Phase 3 Trial Comparing Surgery Alone to Chemotherapy Followed by Surgery for Oral Cavity Squamous Cell Cancer with Advanced Lymph Node Involvement
Led by All India Institute of Medical Sciences, Jodhpur · Updated on 2025-03-04
346
Participants Needed
7
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying oral squamous cell carcinoma, focusing on patients with advanced nodal disease N2-N3 who are operable and present biologically aggressive tumors. The study aims to evaluate whether adding induction chemotherapy before surgery improves 2-year disease-free survival compared to upfront surgery alone. This phase 3, open-label, multi-center randomized controlled trial addresses previous trial limitations by selecting a more homogenous patient group likely to benefit from chemotherapy. Secondary goals include assessing overall survival, treatment response, compliance, toxicity, postoperative complications, quality of life, and tumor biobanking for future research.
The study compares two treatment approaches. The standard arm involves surgery wide local excision with comprehensive neck dissection followed by adjuvant radiotherapy with or without concurrent chemotherapy. The experimental arm adds two cycles of induction chemotherapy using TPF or TPX regimens before surgery and similar adjuvant treatment. Patients will receive standard care according to current guidelines, with surgery timed after assessing chemotherapy response.
Participants aged 18 to 75 with confirmed operable oral squamous cell carcinoma and advanced nodal involvement will be followed for up to five years. Researchers will monitor disease-free survival at two years as the primary outcome, alongside overall survival, treatment completion, toxicity, quality of life assessments over multiple timepoints, and surgical morbidity. Tumor and blood samples will be collected for biobanking. Safety and quality of life will be tracked regularly, including early and late radiotherapy-related toxicities and financial impact questionnaires.
CONDITIONS
Brief Title
Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:
Research Team
D
Dharma R Poonia, MS DNB
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical stage cT1-4a, cN2-N3, M0 as per UICC 2018
No distant metastases on chest X-ray or CT thorax
ECOG performance status of 0 to 2
No contraindication to cisplatin or radiotherapy
Eligible for definitive curative intent treatment after multidisciplinary tumor board discussion
Adequate organ function including hemoglobin > 9 gm/dl, ANC ≥ 1500/cmm3, platelets ≥ 100000/cmm3, liver and kidney function within specified limits
You will not qualify if you...
Pregnant individuals
History of moderate to severe hearing loss
Previous malignancy except non-melanoma skin cancers or cervical carcinoma in situ
Weight loss exceeding 15% in the last 6 months
Known infection with HIV, hepatitis B, or hepatitis C
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 cycles of chemotherapy followed by surgery and adjuvant treatment
Participants receive either upfront surgery with adjuvant treatment or induction chemotherapy followed by surgery and adjuvant treatment, depending on their assigned group.
Chemotherapy visits over 6 weeks and surgery visit
Follow-up
Duration - Up to 2 years
Participants are monitored for disease progression, survival, treatment toxicity, quality of life, and other outcomes after treatment completion.
Multiple follow-up visits including assessments at 3, 6, 12, 18, 24 months and beyond
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing Four vs Two Courses of Pembrolizumab with Carboplatin and Albumin-binding Paclitaxel Before Surgery in Resectable Head and Neck Squamous Cell Carcinoma T3 or T4, N0
Reduced Radiation and Chemotherapy Followed by Planned Neck Dissection Surgery for Head and Neck Cancer Patients Without Tumor Hypoxia
Phase II Study of Pembrolizumab Combined With Tumor DNA-Guided Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Follow-Up Study on AI-Based and Conventional Physiotherapy Effects
on Physical Function, Quality of Life, and Return to Work in Oral Cancer Patients
at 3 and 9 Months After Treatment
Evaluating an AI System for Measuring Mouth and Neck-Shoulder Movement in Healthy Adults with Oral Cancer
Study of AI-Guided Physiotherapy to Improve Mouth, Shoulder, and Physical Function in Adults with Oral Cancer
Phase II Study on the Effect of Antibiotics Metronidazole and Chlorhexidine on Bacteria in Tumors of Oral Cancer Surgery Patients
Collection and Study of Tissue Samples for Head and Neck Disorders to Support Research
Pilot Study of Brodalumab to Treat Immune-Related Side Effects in Adults with Advanced Solid Tumors
Phase II Trial of Extended Chemotherapy Based on Circulating Tumor Cell Counts
for Postoperative Patients With ENE-Positive Oral Cavity Cancer
After Completing Adjuvant Chemoradiotherapy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): a phase 3 multicentre randomised controlled trial.
Dharma Ram Poonia, Amit Sehrawat, Jeewan Ram Vishnoi...